Zenas BioPharma Q2 FY26 net loss widens to $111.5 million; revenue rises to $1 million - ZBIO News | RalliesZenas BioPharma Q2 FY26 net loss widens to $111.5 million; revenue rises to $1 million
Z
ZBIO• Regulatory update and liquidity
- The FDA accepted obexelimab’s IgG4-RD BLA with a May 27, 2027 PDUFA date.
- Cash and investments totaled $673.9 million.
Q2 loss widens as spending increases
- Zenas posted Q2 2026 net loss of $111.5 million, widening from $52.2 million a year earlier.
- Revenue was $1 million, swinging from no revenue, tied to a development milestone under its Tenacia agreement for ZB005.
- Research and development expense climbed to $62.9 million from $43 million, on higher clinical trial, regulatory, and personnel costs.
- General and administrative expense rose to $15.7 million from $12.1 million, reflecting higher headcount and pre-commercialization spending.
•
